Clinical trial
Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
NCT00260689 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00260689 |
|---|---|
| Title | Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia |
| Official title | A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Immunosuppresion, Thrombocytopenia, Pancytopenia, Neutropenia |
| Intervention type | Biological, Drug |
| Interventions | Anti-thymocyte globulin (rabbit), Anti-thymocyte globulin (horse), Cyclosporine, Alemtuzumab |
| Enrollment | 136 |
| Start date | Nov 28, 2005 |
| Primary completion | May 4, 2016 |
| Completion | May 4, 2016 |
| First posted | Dec 1, 2005 |
| Last update posted | Jun 8, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: